Journal of Personalized Medicine最新文献

{"title":"Clinical Pharmacogenetics: Results After Implementation of Preemptive Tests in Daily Routine.","authors":"Xando Díaz-Villamarín, María Martínez-Pérez, María Teresa Nieto-Sánchez, Emilio Fernández-Varón, Alicia Torres-García, Isabel Blancas, José Cabeza-Barrera, Rocío Morón","doi":"10.3390/jpm15060245","DOIUrl":"10.3390/jpm15060245","url":null,"abstract":"<p><p><b>Background/Objectives:</b> The clinical implementation of pharmacogenetics (PGx) remains limited, even for well-established drug-gene interactions. In addition to insufficient infrastructure and PGx education among healthcare professionals, there is currently no consensus regarding which genetic variants should be tested, the most appropriate testing approach (e.g., single-gene vs. multi-gene panels), or how to translate genotypes into actionable therapeutic recommendations. <b>Methods:</b> We describe the implementation of PGx in real daily clinical routine at a single institution to guide other centers. We analyze the drug-gene interactions and genetic variants included in our program based on allelic, genotypic, and phenotypic frequencies, resulting therapeutic recommendations. Linkage disequilibrium and haplotype analyses are also performed. <b>Results and Conclusions:</b> PGx testing was primarily requested by the oncology department. Not all variants included in typical panels had clinical utility in our setting. We do not recommend testing <i>CYP2C19</i><i>*17</i> prior to clopidogrel prescription, as it does not translate into a dosing recommendation. <i>TPMT*3B</i> may be considered just to confirm <i>TPMT*3A</i> due to its linkage with <i>TPMT</i>*3C. Similarly, we do not recommend the routine testing of <i>CYP2C9*2</i> prior to siponimod prescription, as it does not inform therapeutic decisions according to the current drug label.</p>","PeriodicalId":16722,"journal":{"name":"Journal of Personalized Medicine","volume":"15 6","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12194548/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144484795","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Can Radiomics Predict Pathologic Complete Response After Neoadjuvant Chemoradiotherapy for Rectal Cancer? A Systematic Review and Meta-Analysis of Diagnostic-Accuracy Studies.","authors":"Fotios Seretis, Antonia Panagaki, Stavroula Tzamouri, Tania Triantafyllou, Charikleia Triantopoulou, Dimitrios Theodorou","doi":"10.3390/jpm15060244","DOIUrl":"10.3390/jpm15060244","url":null,"abstract":"<p><p><b>Background:</b> The rectal cancer treatment paradigm is rapidly changing with the advent of total neoadjuvant therapy and non-operative management approaches in responders. A good clinical response to neoadjuvant treatment documented by magnetic resonance imaging, endoscopy and clinical examination corresponds, to a large extent, to a pathologic complete response, as assessed in surgical specimens. <b>Methods:</b> We undertook a systematic review and meta-analysis on the MRI-based omics approach to predicting pathologic complete responses. <b>Results:</b> A total of 29 studies with relevant data available reporting on a total of 4486 patients were eligible for meta-analysis. The calculated values for the area under the curve in receiver operator curves of diagnostic accuracy for radiomics-only and radiomics-combined-with-clinical-data models were 0.80 and 0.88, respectively, for studies incorporating baseline imaging data only. The value for studies using delta radiomic data was 0.86, and those for studies using data from the post-neoadjuvant setting were 0.75 and 0.83, respectively, for the radiomics-only and radiomics-combined-with-clinical-data models. <b>Conclusions:</b> Radiomics-based prediction models for pathologic complete response assessment might further enable individualized treatment decisions to be made in patients with rectal cancer.</p>","PeriodicalId":16722,"journal":{"name":"Journal of Personalized Medicine","volume":"15 6","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12193717/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144484794","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Viglianisi et al. The Emerging Role of Salivary Oxidative Stress Biomarkers as Prognostic Markers of Periodontitis: New Insights for a Personalized Approach in Dentistry. <i>J. Pers. Med.</i> 2023, <i>13</i>, 166.","authors":"Gaia Viglianisi, Gianluca Martino Tartaglia, Simona Santonocito, Mariacristina Amato, Alessandro Polizzi, Marco Mascitti, Gaetano Isola","doi":"10.3390/jpm15060243","DOIUrl":"10.3390/jpm15060243","url":null,"abstract":"<p><p>Following discussions between the Editorial Board and the authors, the original published references no [...].</p>","PeriodicalId":16722,"journal":{"name":"Journal of Personalized Medicine","volume":"15 6","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12194269/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144484798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Pharmacological Treatments on Rheumatoid Arthritis-Associated Diffuse Interstitial Lung Disease: A Systematic Review and Meta-Analysis.","authors":"Ariam A Muarif, Rana Algahtani, Lujain H Alghamdi, Sarah S Alghamdi, Lama Al Nemer, Reman Alsaqrah, Yazeed Alsulami, Maha Alsharif, Dana Alznbagi, Lena Aljehani, Ziyad Alsaeedi, Sultan Alghamdi, Taif A Sayel, Basma Al Ghamdi, Ali Al Bshabshe","doi":"10.3390/jpm15060239","DOIUrl":"10.3390/jpm15060239","url":null,"abstract":"<p><p><b>Background</b>: Interstitial lung disease (ILD) is a prominent complication in the course of rheumatoid arthritis (RA), with a prevalence ranging from 5% to 60% and several phenotypes. The existing knowledge on the impact of different pharmacological interventions in individuals with rheumatoid arthritis-related interstitial lung disease (RA-ILD) is inconclusive, and this variable response to treatment highlights the need for a personalized approach to the management of RA-associated ILD. Therefore, we aimed to evaluate the therapeutic effect and safety of different pharmacological agents, including conventional synthetic DMARDs (Cs DMARDs), biologic DMARDs (bDMARDs), targeted synthetic DMARDs (Ts DMARDs), and antifibrotic agents, in patients with RA-ILD. <b>Method</b>: This systematic review and meta-analysis searched for available randomized controlled trials (RCTs) and prospective cohort studies. A search was performed in the PubMed, Google Scholar, and Cochrane Central Register of Controlled Trials (CENTRAL) databases. Eligible studies comprised those involving hospitalized patients diagnosed with RA-ILD, regardless of concomitant medications, who were of adult age (≥18 years); the studies measured the effect of pharmacological interventions, including methotrexate, leflunomide, tumor necrosis factor inhibitors (anti-TNF), abatacept, rituximab, JAK inhibitors, and antifibrotic agents, compared to placebo or other therapies for RA. <b>Results</b>: Out of 446 studies from 2002 to 2024, only 16 were included in this systematic review, including 14 prospective cohort studies and 2 placebo-controlled studies. Unfortunately, no RCTs were found that address our research question. The most relevant studies (<i>n</i> = 4) were performed in different countries (mainly Spain and the UK), with sample sizes varying from 23 to 381 patients (total: 2199 patients). The current study reveals that non-anti-TNF biologics were associated with a decreased risk of radiologic progression, while advanced therapies improved disease-related outcomes in patients requiring oxygen therapy. Methotrexate and other DMARDs were found to have inconsistent effects on ILD progression and mortality. <b>Conclusions</b>: Our review supports the integration of personalized medicine into the management of RA-ILD. By considering patient-specific factors and therapeutic responses, clinicians can better tailor interventions. We confirmed the high methodological quality of the trials, yielding solid evidence for the clinical management of RA-ILD. This review adds to the existing literature by identifying nintedanib as a potential disease-modifying therapy with the potential to slow the progression of lung disease.</p>","PeriodicalId":16722,"journal":{"name":"Journal of Personalized Medicine","volume":"15 6","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12194092/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144484820","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Artificial Intelligence in the Assessment and Grading of Acne Vulgaris: A Systematic Review.","authors":"Daniele Omar Traini, Gerardo Palmisano, Cristina Guerriero, Ketty Peris","doi":"10.3390/jpm15060238","DOIUrl":"10.3390/jpm15060238","url":null,"abstract":"<p><p>Acne vulgaris is a common dermatological condition, particularly affecting adolescents during critical developmental stages, which may have lasting psychosocial impacts. Traditional assessments, including global severity grading and lesion counting, are limited by subjectivity and time constraints. <b>Background/Objectives</b>: This review aims to systematically assess the recent advancements in artificial intelligence (AI) applications for acne diagnosis, lesion segmentation/counting, and severity grading, highlighting the potential of AI-driven methods to improve objectivity, reproducibility, and clinical efficiency. <b>Methods</b>: A comprehensive literature search was conducted across PubMed, Scopus, arXiv, Embase, and Web of Science for studies published between 1 January 2017 and 1 March 2025. The search strategy incorporated terms related to \"acne\" and various AI methodologies (e.g., \"neural network\", \"deep learning\", \"convolutional neural network\"). Two independent reviewers screened 345 articles, with 29 studies ultimately meeting inclusion criteria. Data were extracted on study design, dataset characteristics (including internal and publicly available resources such as ACNE04 and AcneSCU), AI architectures (predominantly CNN-based models), and performance metrics. <b>Results</b>: While AI-driven models demonstrated promising accuracy, as high as 97.6% in controlled settings, the limited availability of large public datasets, the predominance of data from specific ethnic groups, and the lack of extensive external validation underscore critical barriers to clinical implementation. <b>Conclusions</b>: The findings indicate that although AI has the potential to standardize acne assessments, reduce observer variability, and enable self-monitoring via mobile platforms, significant challenges remain in achieving robust, real-world applicability. Future research should prioritize the development of large, diverse, and publicly accessible datasets and undertake prospective clinical validations to ensure equitable and effective dermatological care.</p>","PeriodicalId":16722,"journal":{"name":"Journal of Personalized Medicine","volume":"15 6","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12194645/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144484764","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of Multiple State-of-the-Art Large Language Models for Patient Education Prior to CT and MRI Examinations.","authors":"Semil Eminovic, Bogdan Levita, Andrea Dell'Orco, Jonas Alexander Leppig, Jawed Nawabi, Tobias Penzkofer","doi":"10.3390/jpm15060235","DOIUrl":"10.3390/jpm15060235","url":null,"abstract":"<p><p><b>Background/Objectives</b>: This study compares the accuracy of responses from state-of-the-art large language models (LLMs) to patient questions before CT and MRI imaging. We aim to demonstrate the potential of LLMs in improving workflow efficiency, while also highlighting risks such as misinformation. <b>Methods</b>: There were 57 CT-related and 64 MRI-related patient questions displayed to ChatGPT-4o, Claude 3.5 Sonnet, Google Gemini, and Mistral Large 2. Each answer was evaluated by two board-certified radiologists and scored for accuracy/correctness/likelihood to mislead using a 5-point Likert scale. Statistics compared LLM performance across question categories. <b>Results</b>: ChatGPT-4o achieved the highest average scores for CT-related questions and tied with Claude 3.5 Sonnet for MRI-related questions, with higher scores across all models for MRI (ChatGPT-4o: CT [4.52 (± 0.46)], MRI: [4.79 (± 0.37)]; Google Gemini: CT [4.44 (± 0.58)]; MRI [4.68 (± 0.58)]; Claude 3.5 Sonnet: CT [4.40 (± 0.59)]; MRI [4.79 (± 0.37)]; Mistral Large 2: CT [4.25 (± 0.54)]; MRI [4.74 (± 0.47)]). At least one response per LLM was rated as inaccurate, with Google Gemini answering most often potentially misleading (in 5.26% for CT and 2.34% for MRI). Mistral Large 2 was outperformed by ChatGPT-4o for all CT-related questions (<i>p</i> < 0.001) and by ChatGPT-4o (<i>p</i> = 0.003), Google Gemini (<i>p</i> = 0.022), and Claude 3.5 Sonnet (<i>p</i> = 0.004) for all CT Contrast media information questions. <b>Conclusions</b>: Even though all LLMs performed well overall and showed great potential for patient education, each model occasionally displayed potentially misleading information, highlighting the clinical application risk.</p>","PeriodicalId":16722,"journal":{"name":"Journal of Personalized Medicine","volume":"15 6","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12194482/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144484796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Molecular Biomarkers for the Diagnosis and Prognostication of Pancreatic Ductal Adenocarcinoma.","authors":"James Sun, Morcos A Awad, Jennifer Hwang, Anthony M Villano","doi":"10.3390/jpm15060236","DOIUrl":"10.3390/jpm15060236","url":null,"abstract":"<p><p>Pancreatic ductal adenocarcinoma (PDAC) remains among the most aggressive malignancies in the United States. Advances in treatments have slowly increased survival rates; however, outcomes remain dismal, largely due to the insidious onset of the disease and lack of screening tests leading to diagnosis at more advanced disease stages. As we better understand the molecular mechanisms that drive PDAC, we can leverage this technology for early detection of new PDAC or recurrences and find more effective methods to track treatment response. Liquid biopsies are increasingly common for the treatment of many malignancies, leveraging better technology to detect scant quantities of circulating tumor cells (CTCs) or byproducts of tumor biology (e.g., exosomes and microRNA [miRNA]) in the blood stream. When combined with existing biomarkers like CA 19-9, there is promising research that improved diagnostic modalities may be available in the future. Furthermore, these technologies are being leveraged to better prognosticate patients with PDAC and potentially monitor treatment responses not captured by cross-sectional imaging, which may allow for real-time changes in therapeutic strategy. This manuscript will review the molecular mechanisms that drive PDAC development and the biomarkers available for diagnosis and prognostication. Much of the data presented is still investigational, though many trials are ongoing to translate these studies for clinical use.</p>","PeriodicalId":16722,"journal":{"name":"Journal of Personalized Medicine","volume":"15 6","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12193973/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144484826","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inflammatory Arthritis and the Environment: Causes and Consequences of Spondyloarthritis.","authors":"Maurizio Benucci, Edda Russo, Francesca Li Gobbi, Mariangela Manfredi, Maria Infantino","doi":"10.3390/jpm15060237","DOIUrl":"10.3390/jpm15060237","url":null,"abstract":"<p><p>The extensive research and studies conducted over the past decade have greatly improved our comprehension of the pathogenesis and risk factors associated with Spondyloarthritis (SpA). In addition, they have contributed to the advancement of novel therapeutic approaches. Although genetics still represents the primary risk factor for SpA, increasing evidence presented in this review suggests that environmental factors-such as air pollution, smoking, gut microbiota (GM), infections, and diet-also contribute to its pathogenesis. In detail, environmental particulate matters (PMs), which include ligands for the aryl hydrocarbon receptor-a cytosolic transcription factor responsive to toxic substances-facilitate the differentiation of T Helper 17 (Th17) cells, potentially exacerbating the autoinflammatory processes associated with SpA. Furthermore, smoking influences both the cellular and humoral aspects of the immune response, resulting in leukocytosis, impaired leukocyte functionality, and a decrease in various cytokines and soluble receptors, including interleukin (IL) 15, IL-1 receptor antagonist (IL-1Ra), IL-6, soluble IL-6 receptor (sIL-6R), as well as the vascular endothelial growth factor (VEGF) receptor. Studies have indicated that patients with SpA exhibit an increased prevalence of antibodies directed against a conserved epitope shared by the human leukocyte antigen B27 (HLA-B27)- and <i>Klebsiella nitrogenase</i>, in comparison to HLA-B27-positive controls. Additionally, current evidence regarding the GM suggests the presence of a gut-joint-skin axis, wherein the disruption of the mucosal barrier by specific bacterial species may enhance permeability to the gut-associated lymphoid tissue (GALT), resulting in localized inflammation mediated by Th1 and Th17 cells, as well as IL-17A. Finally, this review discusses the role of diet in shaping the microbial composition and its contribution to the pathogenesis of SpA. A comprehensive understanding of the mechanisms by which environmental factors influence the pathogenesis and progression of the disease could facilitate the development of novel personalized therapies targeting both external and internal environmental exposures, such as the gut microbial ecosystem.</p>","PeriodicalId":16722,"journal":{"name":"Journal of Personalized Medicine","volume":"15 6","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12194617/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144484824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Spinal Arachnoid Cysts: A Single-Center Preliminary Surgical Experience with a Rare and Challenging Disease.","authors":"Alessio Iacoangeli, Love Chibuzor Ilochonwu, Giulia Mazzanti, Gabriele Polonara, Lauredana Ercolani, Alessandra Marini, Michele Luzi, Roberto Trignani, Stefano Bruni, Edoardo Barboni, Maurizio Gladi, Maurizio Iacoangeli, Denis Aiudi","doi":"10.3390/jpm15060234","DOIUrl":"10.3390/jpm15060234","url":null,"abstract":"<p><p><b>Background:</b> Spinal arachnoid cyst development (SAC) is a rare and debilitating disease with a non-well-defined treatment strategy: a series of five patients diagnosed with SAC and submitted to neurosurgical treatment was retrospectively analyzed. <b>Objectives</b>: SACs represent 1-2% of all spinal neoplasms; they can be extradural, intradural, or intramedullary, with intradural arachnoid cysts (IDACs) comprising only 10% of these cases. The rarity of SACs and the lack of consensus on the best treatment strategies represent a care challenge: the aim of this study is to explore the effectiveness and outcomes of the neurosurgical management in patients with SACs treated at our institution. <b>Methods</b>: Adult patients who underwent surgical treatment for SACs between January 2020 and December 2023 were included in the study: clinical onset, imaging, surgical technique, and neurological long-term status were retrospectively analyzed. <b>Results</b>: Five patients (three males, two females; average age 53.4 years) were included. The most common symptoms described were paresthesia, gait disturbances, and back pain. Radiological imaging indicated that most cysts were at the thoracic level. Surgical interventions primarily involved cyst resection and adhesiolysis. Post-operative outcomes showed overall improvement or stability in Karnofsky Performance Status (KPS) and American Spinal Injury Association Impairment Scale (ASIA) scores in the majority of cases, although complications and recurrences occurred. <b>Conclusions</b>: Surgical resection combined with adhesiolysis may prevent the worsening of neurological impairment and potentially improve pain control and clinical outcomes in patients with SACs. However, careful and tailored management is required due to the high potential of complications and recurrences.</p>","PeriodicalId":16722,"journal":{"name":"Journal of Personalized Medicine","volume":"15 6","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12194452/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144484858","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enhancing the Outcomes of Temporalis Fascia Tympanoplasty Using Autologous Platelet-Rich Plasma and Gel: A Randomized Controlled Trial.","authors":"Nejc Steiner, Domen Vozel, Nina Bozanic Urbancic, Kaja Troha, Andraz Lazar, Veronika Kralj-Iglic, Saba Battelino","doi":"10.3390/jpm15060233","DOIUrl":"10.3390/jpm15060233","url":null,"abstract":"<p><p><b>Objectives:</b> This study aimed to investigate the impact of platelet-rich plasma (PRP) and platelet-rich gel (PRG) on tympanic membrane closure rates, hearing improvement, and quality of life following tympanoplasty. <b>Methods:</b> Seventy-two patients with chronic tympanic membrane perforations were enrolled in a double-blinded, randomized controlled trial at a single tertiary referral center. All patients underwent tympanoplasty using a temporalis fascia graft and were randomly assigned to one of two groups: one group received standard tympanoplasty alone, while the other received intraoperative application of autologous PRP and PRG, in addition to the standard procedure. <b>Results:</b> The PRP group demonstrated a significantly higher rate of complete tympanic membrane closure compared to the control group (32/36; 88.9% vs. 24/36; 66.7%; <i>p</i> < 0.05). Bone conduction hearing remained unchanged in both groups, while air conduction hearing improved significantly from pre- to post-treatment in each group. However, the difference in air conduction improvement between the PRP group and the control group was not statistically significant (PRP group: Mdn = -8.25; control group: Mdn = -12.20; U = 618; z = -0.54; <i>p</i> = 0.30). Quality of life improved in both the PRP and control groups; however, the difference between the groups was not statistically significant (PRP group: 10.44 ± 10.46; control group: 10.47 ± 8.22; 95% CI [-4.45; 4.40]; <i>t</i>(66) = -0.01; <i>p</i> = 0.16). <b>Conclusions:</b> Our findings suggest that intraoperative application of autologous PRP and PRG may improve tympanoplasty outcomes, particularly in cases with lower expected success rates or when performing minimally invasive transcanal procedures under local anesthesia. However, variability in PRP preparation, application methods, and graft materials across studies limits direct comparisons. Standardized protocols and further controlled studies are necessary to clarify PRP's clinical value in tympanoplasty.</p>","PeriodicalId":16722,"journal":{"name":"Journal of Personalized Medicine","volume":"15 6","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12194785/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144484802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}